@article{oai:nagasaki-u.repo.nii.ac.jp:00026907,
 author = {Dotsu, Yosuke and Yamaguchi, Hiroyuki and Fukuda, Minoru and Suyama, Takayuki and Honda, Noritaka and Umeyama, Yasuhiro and Taniguchi, Hirokazu and Gyotoku, Hiroshi and Takemoto, Shinnosuke and Tagawa, Ryuta and Ogata, Ryosuke and Tomono, Hiromi and Shimada, Midori and Senju, Hiroaki and Nakatomi, Katsumi and Nagashima, Seiji and Soda, Hiroshi and Ikeda, Hiroaki and Ashizawa, Kazuto and Mukae, Hiroshi},
 issue = {18},
 journal = {Journal of Clinical Medicine},
 month = {Sep},
 note = {Background: Single-agent amrubicin chemotherapy is a key regimen, especially for small cell lung cancer (SCLC); however, it can cause severe myelosuppression. Purpose: The purpose of this study was to determine the real-world incidence of febrile neutropenia (FN) among patients treated with single-agent amrubicin chemotherapy for thoracic malignancies. Patients and methods: The medical records of consecutive patients with thoracic malignancies, including SCLC and non-small cell lung cancer (NSCLC), who were treated with single-agent amrubicin chemotherapy in cycle 1 between January 2010 and March 2020, were retrospectively analyzed. Results: One hundred and fifty-six patients from four institutions were enrolled. Their characteristics were as follows: median age (range): 68 (32–86); male/female: 126/30; performance status (0/1/2): 9/108/39; SCLC/NSCLC/others: 111/30/15; and prior treatment (0/1/2/3-): 1/96/31/28. One hundred and thirty-four (86%) and 97 (62%) patients experienced grade 3/4 and grade 4 neutropenia, respectively. One hundred and twelve patients (72%) required therapeutic G-CSF treatment, and 47 (30%) developed FN. Prophylactic PEG-G-CSF was not used in cycle 1 in any case. The median overall survival of the patients with FN was significantly shorter than that of the patients without FN (7.2 vs. 10.0 months, p = 0.025). Conclusions: The real-world incidence rate of FN among patients with thoracic malignancies that were treated with single-agent amrubicin chemotherapy was 30%. It is suggested that prophylactic G-CSF should be administered during the practical use of single-agent amrubicin chemotherapy for patients who have already received chemotherapy., Journal of Clinical Medicine, 10(18), art. no. 4221; 2021},
 title = {Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor},
 volume = {10},
 year = {2021}
}